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carcinoma (HCC), describe tumor characteristics and 
treatments pursed for a cohort of individuals with nonal-
coholic steatohepatitis (NASH) cirrhosis. 
METHODS
We conducted a retrospective case-control study of a 
well-characterized cohort of patients among five liver 
transplant centers with NASH cirrhosis with (cases) and 
without HCC (controls).
RESULTS
Ninety-four cases and 150 controls were included. Cases 
were significantly more likely to be male than controls 
(67% vs  45%, P  < 0.001) and of older age (61.9 years 
vs  58 years, P  = 0.002). In addition, cases were more 
likely to have had complications of end stage liver 
disease (83% vs  71%, P  = 0.032). On multivariate 
analysis, the strongest association with the presence 
of HCC were male gender (OR 4.3, 95%CI: 1.83-10.3, 
P  = 0.001) and age (OR = 1.082, 95%CI: 1.03-1.13, 
P  = 0.001). Hispanic ethnicity was associated with 
a decreased prevalence of HCC (OR = 0.3, 95%CI: 
0.09-0.994, P  = 0.048). HCC was predominantly in the 
form of a single lesion with regional lymph node(s) and 
distant metastasis in only 2.6% and 6.3%, respectively. 
Fifty-nine point three percent of individuals with HCC 
underwent locoregional therapy and 61.5% underwent 
liver transplantation for HCC. 
CONCLUSION
Male gender, increased age and non-Hispanic ethnicity 
are associated with HCC in NASH cirrhosis. NASH cirr-
hosis associated HCC in this cohort was characterized 
by early stage disease at diagnosis and treatment with 
locoregional therapy and transplant.
Key words: Hepatocellular carcinoma; Nonalcoholic 
fatty liver disease; Cirrhosis, Gender; Ethnicity
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Core tip: The present paper identifies male gender, 
increased age and non-Hispanic ethnicity as factors 
associated with hepatocellular carcinoma (HCC) in 
nonalcoholic steatohepatitis cirrhosis. In this series, 
HCC in nonalcoholic fatty liver disease cirrhosis was 
diagnosed at an early stage and treated predominantly 
with locoregional therapy and liver transplantation. 
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INTRODUCTION
The burden of nonalcoholic fatty liver disease (NAFLD) 
is substantial. Estimates suggest 75-100 million people 
in the United States have NAFLD, and alarmingly, many 
of these patients are not aware of or evaluated for 
this condition[1,2]. A subset of individuals with NAFLD 
will develop nonalcoholic steatohepatitis (NASH), the 
inflammatory phenotype of NAFLD. Hepatic fibrosis and 
eventual cirrhosis is a consequence of NASH progression, 
particularly in genetically predisposed individuals. NASH 
cirrhosis is projected to be the leading indication for liver 
transplantation in the next 10-20 years[3]. 
Hepatocellular carcinoma (HCC), like NAFLD, is also 
underrecognized. In fact, a recent retrospective study 
suggested that only 20% of patients received appropriate 
surveillance before their HCC diagnosis[4]. Inadequate 
screening is a serious concern for patients with cirrhosis 
of any type. However, recent data suggests that a de-
ficiency in screening may be particularly problematic for 
patients with NAFLD HCC who present at a later tumor 
stage, have shorter survival times, and lower rates of 
liver transplantation[5].
Thus, the convergence of NAFLD and HCC uniquely 
focuses the narrative for providers caring for these 
patients to enhance the screening and diagnosis of 
both diseases. Simultaneously, identifying risk factors 
for HCC development in patients with underlying NASH 
cirrhosis is critically important to improve screening and 
treatment. We have conducted a retrospective case-
control study of a well-characterized cohort of patients 
with NASH cirrhosis with and without HCC in order to 
identify risk factors associated with HCC. We also provide 
tumor characteristics and survival data for this cohort. 
Our data, derived from five academic liver transplant 
centers, highlights patient characteristics associated with 
HCC and enhances the growing body of evidence on HCC 
in the setting NAFLD.
MATERIALS AND METHODS
We conducted a case-control study of individuals with 
NAFLD cirrhosis with and without HCC from five academic 
medical centers in the United States. NAFLD was diag-
nosed between 1991-2015 and all HCC cases were 
diagnosed between 2004-2015. This study was approved 
by the Institutional Review Boards at the respective 
institutions.
A diagnosis of NAFLD cirrhosis was made either (1) 
by histology; or (2) clinically. Clinical NAFLD was defined 
by the exclusion of other causes of chronic liver disease 
and the presence of one or more risk factors for NAFLD 
including diabetes, obesity or ≥ 1 component of the 
metabolic syndrome. The diagnosis of cirrhosis was 
made either by histology or by imaging suggestive of 
cirrhosis (nodular liver, splenomegaly, ascites or varices) 
in combination with laboratory values suggesting portal 
hypertension or impaired synthetic function (platelet count 
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< 150000/µL, albumin < 3.5 g/dL) or complications of 
end-stage liver disease. Characteristic liver histology for 
NASH served as one diagnostic modality; NAFLD Activity 
Score values were not available for all subjects. 
Definition of cases
Cases were individuals with NAFLD cirrhosis and well-
characterized HCC. HCC was defined by histology or 
imaging consistent with Organ Procurement and Trans-
plantation Network criteria[6].
Definition of controls
Controls were defined as individuals meeting criteria for 
NASH cirrhosis but without evidence of HCC on imaging 
within one year following the diagnosis of cirrhosis. For 
each case, depending on the availability, we enrolled 1-3 
controls from the same institution. Cases and controls 
were matched for the year of enrollment, i.e., ascer-
tainment of absence of HCC by imaging in the controls 
was in the same year as the HCC diagnosis in the cases. 
Data collection
Charts were reviewed for weight, height, body mass 
index (BMI) and co-morbid disease including diabetes 
mellitus, hypertension, dyslipidemia, cardiovascular dis-
ease, obstructive sleep apnea, polycystic ovary syndrome 
and obesity. Complications of liver disease were also 
recorded including the presence of ascites, spontaneous 
bacterial peritonitis, hepatorenal syndrome, hepatic 
encephalopathy and gastroesophageal varices. These 
complications were combined in to a composite cirrhosis 
complication variable. Use of medications including 
metformin, pioglitazone, vitamin E, HMG-CoA reductase 
inhibitors (“statins”) was also collected. Laboratory values 
for platelet count, INR, fasting insulin, fasting glucose, 
creatinine, alkaline phosphatase, alanine aminotran-
sferase (ALT), aspartate aminotransferase, total bilirubin, 
albumin, total cholesterol, low-density lipoprotein level, 
high-density lipoprotein level, triglycerides, glycosylated 
hemoglobin (A1C), ferritin, alpha-fetoprotein, and model 
for end-stage liver disease (MELD) score.MELD score was 
calculated according to the published formula[7].
Pathology reports were reviewed for the presence 
of HCC as well as TMN classification of malignant tumor 
status, differentiation status, vascular and/or perineural 
invasion and lymph node involvement. Imaging including 
ultrasound, computerized tomography scan or magnetic 
resonance imaging was reviewed for tumor number, size 
and location. 
Statistical analysis
All statistical analyses were performed using SAS 
software, version V.9.2 (SAS Institute, Cary, NC). Con-
tinuous variables were analyzed using a Student’s t-test 
for normally distributed variables and a Wilcoxon rank 
sum test for variables that were not normally distributed. 
Categorical variables were analyzed using a χ 2 test or 
Fisher’s exact test as appropriate. Nominal, two-sided 
P values were used and were considered statistically 
significant if P < 0.05. The final model was selected by 
combining clinical judgment and statistical assessment. 
We included variables with P < 0.1 in univariate analysis 
and variables that are considered as known confounders. 
All analyses were carried out using SAS 9.4 (SAS In-
stitute, Cary, NC) and Stata 13.1 (Stata Corp., College 
Station, TX). 
RESULTS
Baseline characteristics
Two hundred and forty-four individuals (94 cases and 150 
controls) were included. Individuals were predominantly 
male (54.7%), and Caucasian (81.8%) with a mean age 
of 59 years. Diabetes (69.5%), dyslipidemia (47.9%) 
and hypertension (60.1%) were frequent. Mean BMI was 
33.5 kg/m2 and mean MELD score was 12. 
Seventy-five point four percent had a complication of 
cirrhosis with the most frequent being gastroesophageal 
varices (58.0%), ascites (48.6%) and encephalopathy 
(39.6%). Hepatorenal syndrome and spontaneous 
bacterial peritonitis were infrequent (3.3% and 4.2%, 
respectively). 
Characteristics of cases and controls: Univariate 
analysis
Ninety-four cases and 150 controls were included in the 
present study. Cases were significantly more likely to 
be male than controls (67% vs 45%, P < 0.001) and 
be of older age (mean, 61.9 ± 9.4 vs 58.0 ± 9.9, P = 
0.002). In addition, cases were more likely to have had 
complications of end-stage liver disease including ascites, 
SBP, HRS, gastroesophageal varices or encephalopathy 
(composite 83% vs 71%, P = 0.032). There was no 
difference between cases and controls by comorbidities, 
medication use including statins or vitamin E, or bio-
chemical markers such as ALT or MELD score (Table 1). 
Characteristics of cases and controls: Multivariate 
analysis
On multivariate analysis, after adjustment for the re-
levant confounders, the strongest association with the 
presence of HCC among those with NASH cirrhosis was 
male gender (OR = 4.3, 95%CI: 1.83-10.3, P = 0.001). 
In addition, age (OR = 1.082, 95%CI: 1.03-1.13, P = 
0.001) was associated with HCC. Hispanic ethnicity was 
associated with a decreased prevalence of HCC (OR = 0.3, 
95%CI: 0.09-0.994, P = 0.048) (Table 2).
Characteristics of HCC in NAFLD cirrhosis
HCC diagnosed in this cohort of individuals with NASH 
cirrhosis was predominantly in the form of a single lesion 
(median 1.0, IQR 1.0) with a median size of 2.7 cm (IQR 
2.5) (Table 3). Regional lymph node and distant metastasis 
were recorded in only 2.6% and 6.3%, respectively. 
Vascular or perineural invasion was documented in 
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13.9% and 1.3%, respectively. Fifty-five prcent of tumors 
involved a single lobe of the liver, 25.6% were bilobar, 
while the lobar distribution was unknown in 32.4%. 
Treatment for HCC
In this cohort, 59.3% of individuals with HCC underwent 
either locoregional therapy with radiofrequency ablation, 
transarterial chemoembolization or radiation. In addition, 
61.5% of the entire cohort underwent liver transplan-
tation for HCC. Resection was infrequent and took place 
in only 10% of the HCC cohort. Sorafenib and/or palliative 
care was administered in 10% of patients. 
DISCUSSION
NASH cirrhosis is projected to become the leading in-
dication for liver transplantation by 2020, surpassing 
alcohol and chronic hepatitis C infection[3]. Despite its 
public health impact, however, relatively little is known 
about the risk factors for HCC development in NASH 
cirrhosis. The present case-control study sought to 
address this gap by evaluating individuals with NASH 
cirrhosis with and without HCC. 
We found that HCC was associated with male gender 
and older age. There was no difference between cases 
and controls with regards to comorbidities, prescription 
medications, vitamin E use, or biochemical markers such 
as ALT or MELD score. Surprisingly, the Hispanic ethnicity 
conferred a decreased risk of HCC. 
The observed differences in sex and age are con-
sistent with prior studies. Ascha et al[8] compared 
patients with HCC secondary to NASH cirrhosis to those 
with HCV cirrhosis and HCC. Compared to those with 
HCV, individuals with NASH and HCC were significantly 
older and had a trend toward an increased risk of HCC in 
men. Bugianesi et al[9] also evaluated risk factors for HCC 
in a cohort of 641 individuals with chronic liver disease 
of varying etiologies. Six point nine percent of the cohort 
had cryptogenic cirrhosis largely attributed to NASH. HCC 
in cryptogenic cirrhosis was associated with older age 
although no difference in gender was seen. These studies 
also found that HCC in NASH cirrhosis/cryptogenic cirr-
hosis was associated with BMI, obesity and diabetes 
mellitus. The present study did not find associations 
between diabetes, obesity, BMI or insulin resistance. 
Our use of NASH cirrhosis controls with high prevalence 
of diabetes and obesity may account for this difference 
as prior studies have compared NASH patients who are 
often characterized by diabetes and obesity to those with 
other forms of chronic liver disease among whom these 
comorbidities are less frequent. 
Metabolic stress including development of the meta-
bolic syndrome is not only associated with increased risk 
of cancer in general, but with risk for HCC. Presumably, 
most NAFLD patients meet criteria for diagnosis of the 
metabolic syndrome, yet a great proportion of these 
patients do not develop HCC. The present study did not 
find a significant difference in comorbidities between 
cases and controls. Just as only a subset of NAFLD patients 
progress to NASH, this lends further support to a genetic 
determinant for development of HCC within NAFLD. 
Investigation of genetic alterations in insulin signaling 
including the PI3K-AKT-PTEN pathway and other factors 
Variable Univariate 
P  value
Multivariate OR 
95%CI
Multivariate 
P  value
Age    0.002     1.08 (1.032-1.13)    0.001
Gender < 0.001     4.34 (1.83-10.31) < 0.001
BMI  0.22   0.96 (0.90-1.02)  0.20
Ethnicity  0.15     0.300 (0.090-0.994)    0.045
Platelet count  0.14 1.004 (1.00-1.01)  0.14
CVD  0.09   1.21 (0.61-2.41)  0.58
Gastroesophageal varices  0.07   1.43 (0.63-3.21)  0.39
Complications of cirrhosis  0.03   1.15 (0.43-3.02)  0.78
Table 2  Variables associated with presence of hepatocellular 
carcinoma on multivariate analysis1
1The final model was selected by combining clinical judgment and 
statistical assessment. We included variables with P < 0.1 in univariate 
analysis and variables that are considered as known confounders. CVD: 
Cardiovascular disease; BMI: Body mass index.
Characteristic Case 
(n  = 94)
Control 
(n  = 150)
P  value
Age, yr (mean ± SD) 61.9 ± 9.4 58.0 ± 9.9    0.002
Gender Female 33%    55% < 0.001
Male 67%    45%
Race White 85% 80.0%    0.605
Black   1%    17%
Other 14%      3%
Ethnicity Not 
Hispanic
82%    90%    0.149
Hispanic 18%    10%
Diabetes mellitus Yes 74%    67%    0.237
No 26%    33%
Hypertension Yes 61%    60%    0.888
No 39%    40%
Dyslipidemia Yes 50%    47%    0.609
No 50%    53%
Cardiovascular disease Yes 28%    19%    0.093
No 72%    81%
Metformin use Yes 40%    37%    0.660
No 60%    63%
Statin use Yes 25%    21%    0.401
No 75%    79%
Vitamin E use Yes 11%      9%    0.620
No 89%    91%
Ascites Yes 51%    47%    0.628
No 49%    53%
Gastroesophageal varices Yes 66%    53%    0.072
No 34%    47%
Hepatic encephalopathy Yes 40%    40%    0.995
No 60%    60%
Complications of 
cirrhosis
Yes 83%    71%    0.032
No 17%    29%
BMI (kg/m2) 32.8 ± 5.8   33.9 ± 7.3    0.222
ALT (IU/L) (mean ± SD)   43.3 ± 25.4   42.18 ± 37.3    0.819
MELD score (mean ± SD) 11.6 ± 4.4 12.39 ± 4.8    0.382
Table 1  Characteristics of cases and controls
BMI: Body mass index; ALT: Alanine aminotransferase; MELD: Model for 
end-stage liver disease.
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in inflammatory pathways including NF-KB may be 
promising[10-12] and possible with a prospective study in a 
similar cohort of subjects.
Genetic variation may explain reported racial/ethnic 
disparities. Racial/ethnic disparities have been reported 
both in NAFLD and HCC: Hispanics tend to have a more 
progressive course in NAFLD; and have lower rates of 
curative therapies for HCC[13]. Our finding that Hispanic 
ethnicity was associated with a decreased risk of develop-
ment of HCC within NAFLD is surprising and needs 
confirmation with a larger cohort of individuals with 
NASH and other etiologies of chronic liver disease. Indeed 
among other causes of chronic liver disease, specifically 
hepatitis C, Hispanics are more likely to progress to 
cirrhosis and HCC[14]. The present study is limited by a 
small number of Hispanic patients among both cases 
and controls and further evaluation of this relationship 
between ethnicity and HCC among those with NASH 
cirrhosis is needed. 
The tumors observed in our study were typically a 
single lesion, confined to a single lobe and without any 
invasion to adjacent structures. This is in contrast with a 
recent study by Piscaglia et al[15] who found that NAFLD-
HCC tended to be more advanced when compared to 
HCC in the background of HCV cirrhosis (HCV-HCC). 
The authors concluded that this was a result of delayed 
diagnosis of NAFLD and subsequent lack of screening in 
advanced fibrosis. There was no significant difference in 
mortality when propensity score analysis was performed. 
Certainly, detection of early stage HCC centers around 
appropriate screening. Our patients were established in 
our respective clinics and routinely followed. Resection 
was infrequent and the majority of our patients (61.5%) 
underwent orthotopic liver transplantation. The earlier 
stage observed in our study may be a product of referral 
and/or selection bias, as this cohort was selected from 
tertiary care and transplant medical center populations.
The limitations of our study include its retrospective 
nature; only cirrhotic patients were included in the study 
by design, thus limiting our ability to add to the body 
of data of HCC in the absence of advanced fibrosis. 
Similarly, we did not include HCC arising within other 
etiologies of cirrhosis, and therefore, cannot report 
that our findings are unique to NAFLD but that these 
characteristics play a role in the development of HCC in 
the context of NAFLD cirrhosis. The duration of cirrhosis 
is not known in this cohort given the case- control design 
and absence of longitudinal data. 
In conclusion, the present study found that male 
gender and advanced age were associated with increased 
risk for the development of HCC among individuals with 
NASH cirrhosis whereas Hispanic ethnicity was associated 
with lower risk. Larger cohorts of individuals with HCC, 
from NASH and other etiologies are needed to further 
explore these associations. Additionally, prospective 
studies will help address these factors as predictors 
of HCC development and to risk stratify patients with 
NAFLD at increased risk for HCC who may benefit from 
more intense surveillance for HCC.
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